Cannara Biotech Graduates to Toronto Stock Exchange

Event summary

  • Cannara Biotech received final approval to graduate from the TSX Venture Exchange to the Toronto Stock Exchange (TSX).
  • Shares will commence trading on the TSX under the symbol 'LOVE' starting March 2, 2026.
  • TD Cowen initiated coverage on Cannara as of February 24, 2026.
  • Cannara operates two mega facilities in Québec spanning over 1,600,000 sq. ft. with a potential annualized cultivation output of 100,000 kg.

The big picture

Cannara Biotech's graduation to the TSX marks a significant milestone in its evolution as a public company, enhancing its market visibility and liquidity. This move reflects the progress made by the company and its commitment to building long-term shareholder value. The uplisting is part of a broader trend in the cannabis industry where companies seek to attract institutional investors and improve market positioning.

What we're watching

Market Impact
How the uplisting will affect Cannara's market visibility and liquidity.
Institutional Interest
Whether the graduation to the TSX will attract more institutional investors.
Execution Risk
The pace at which Cannara can sustain its growth strategy post-uplisting.